About Taiho
Our Business
Our Science
July 01, 2021
Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology with New Taiho Smile Support Program
June 09, 2021
Taiho Pharmaceutical Adopts Carbon-Neutral Electricity at Inuyama Plant（PDF：124.7 KB）
Otsuka Group Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-
May 27, 2021
Taiho Pharmaceutical Obtains Approval for an Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi® for Pediatric Patients in Japan（PDF：177.8 KB）
May 10, 2021
Taiho Pharmaceutical Launches New VR Content, "Virtual Patient's Journey" for Doctors, a Simulation of a Palmoplantar Pustulosis Patient's Struggles and Difficulties in Everyday Life
April 02, 2021
FDA Grants Breakthrough Therapy Designation for Taiho Pharmaceutical Originated Futibatinib for Treatment of Advanced Cholangiocarcinoma（PDF：433.6 KB）
March 23, 2021
Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms (Nausea and Vomiting) Associated with Cancer Chemotherapy
March 09, 2021
Taiho Pharmaceutical Announces Personnel Changes（PDF：82.6 KB）
February 22, 2021
Taiho Pharmaceutical's TAS-116, an Oral HSP90 Inhibitor, Shows Significantly Prolonged Progression-Free Survival in Patients with GIST in Phase-III Clinical Trial
February 09, 2021
Office Divisions of Five Otsuka Group Companies to Switch to Green Power（PDF：102.5 KB）
January 18, 2021
Taiho Pharmaceutical Launches Its First Food with Function Claims Product to Counter Cold Hands Among Women
January 15, 2021
Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Base in Switzerland
January 13, 2021
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program
January 12, 2021
Taiho Pharmaceutical Fully Adopts Carbon-Neutral Electricity at Saitama Site（PDF：127.2 KB）
January 05, 2021
Taiho Pharmaceutical Begins Phase III Clinical Trial with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan
